Efficacy and safety of tumour necrosis factor alpha inhibitors in Rheumatoid Arthritis

• Autores: C. Gómez Baraza, F.J. Manero Ruiz, A. Pecondón Español, M. Arenere Mendoza, Iciar Cañamares Orbis
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 3, 2013, págs. 150-157
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To evaluate the efficacy and safety of tumor necrosis factor alpha inhibitors in Rheumatoid Arthritis (RA). Method: An observational and retrospective study conducted on patients with RA treated at a hospital between May 2000 and December 2009. We analyzed the influence of demographic and clinical factors in the effectiveness of treatments and made a comparison between them. We determined the durability of the anti-TNF-alpha agents and adverse reactions. Results: The efficacy study showed improvement in the clinical variables. The survival analysis showed no significant differences depending on the used drug or treatment line. The safety analysis revealed risk of infections. Conclusion: Infliximab, etanercept, and adalimumab are effective drugs for RA therapy, improving symptoms control and showing similar effectiveness between them